Key result
TAVI in patients ≥85 years yields long-term MACE rates comparable to patients <85 years.
Why the study?
While TAVI use is increasing among older populations, evidence on outcomes in the very elderly remains controversial.
Does TAVI in patients aged ≥85 years yield comparable long-term outcomes to patients <85 years with severe symptomatic AS?
Population
210 patients with severe symptomatic AS undergoing TAVI
Comparison
Age ≥85 years vs younger than 85 years
Design
Single-center retrospective cohort study
Follow-up
Mean 4.2 ± 1.4 years
Authors
Loading...
Supports TAVI consideration in selected patients ≥85 years; leaves open generalizability pending randomized data.
Cohort (n=210)
No
Does TAVI in patients aged ≥85 years yield comparable long-term outcomes to patients <85 years with severe symptomatic AS?
Absolute Event Rate: 46.8% vs 41.2%
p-value: p=0.244
TAVI in carefully selected patients aged ≥85 years yields long-term outcomes comparable to younger patients, suggesting advanced age alone should not preclude the procedure.
Amico et al. (2025) conducted a cohort in Severe symptomatic aortic stenosis (n=210). Transcatheter aortic valve implantation (TAVI) in patients aged ≥85 years vs. TAVI in patients aged <85 years was evaluated on Major adverse cardiovascular events (MACE) (p=0.244). TAVI in patients aged ≥85 years yielded long-term major adverse cardiovascular event rates comparable to those in patients <85 years (46.8% vs. 41.2%, p=0.244).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: